GS-834356

**GS-834356** is an investigational **liver-targeted small-molecule allosteric dual inhibitor of acetyl-CoA carboxylase 1 and 2** being developed by **Gilead** for metabolic liver disease, particularly **nonalcoholic fatty liver disease** and **nonalcoholic steatohepatitis**. It has been described as **an analog of firsocostat**, designed to inhibit hepatic de novo lipogenesis and promote fatty acid oxidation, thereby reducing hepatic steatosis and downstream liver injury/fibrosis biology. Publicly available information on this specific code is limited, but published and company-linked materials consistently characterize it as a preclinical-to-clinical-stage ACC1/2 inhibitor used in NASH-related research and combination studies.